Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment strategy and clinical experience.

Peter M L Teo1, Anthony T C Chan

  • 1Department of Clinical Oncology at the Sir YK Pao Cancer Center, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, PR China.

Seminars in Cancer Biology
|November 27, 2002
PubMed
Summary

Nasopharyngeal carcinoma (NPC) treatment, especially for advanced stages, benefits from concurrent cisplatin-radiotherapy. Novel approaches like neoadjuvant chemotherapy and advanced radiotherapy techniques show promise for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same author

A multicentre phase 2 study of trifluridine/tipiracil in recurrent/metastatic platinum resistant nasopharyngeal carcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

JCO global oncology·2026
Same author

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.

Cancer medicine·2026
Same author

The arrival of antibody drug conjugates in nasopharyngeal cancer.

Lancet (London, England)·2025

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Nasopharyngeal carcinoma (NPC) is highly radiosensitive, with early stages achieving high cure rates via radiotherapy.
  • Locoregionally advanced NPC shows high initial radiotherapy control but significant failure rates.
  • Current standard treatment for advanced NPC involves concurrent cisplatin-radiotherapy, with or without adjuvant chemotherapy, improving survival.

Purpose of the Study:

  • To review the current treatment strategies for nasopharyngeal carcinoma.
  • To highlight the efficacy of concurrent chemoradiotherapy in advanced NPC.
  • To explore novel approaches including neoadjuvant chemotherapy and advanced radiotherapy techniques.

Main Methods:

  • Review of existing clinical trials and treatment guidelines for NPC.

Related Experiment Videos

  • Analysis of data on concurrent cisplatin-radiotherapy efficacy.
  • Evaluation of emerging techniques like neoadjuvant chemotherapy and intensity-modulated radiotherapy (IMRT).

    • Main Results:

    • Concurrent cisplatin-radiotherapy significantly improves survival in locoregionally advanced NPC.
    • Neoadjuvant chemotherapy followed by chemoradiotherapy shows encouraging results in Phase II trials.
    • Advanced radiotherapy techniques (IMRT, 3D-CRT) may enhance local control and reduce toxicity.

    Conclusions:

    • Concurrent chemoradiotherapy is the standard of care for advanced NPC.
    • Neoadjuvant chemotherapy followed by chemoradiotherapy represents a promising strategy.
    • Advancements in radiotherapy techniques are crucial for optimizing treatment outcomes in NPC.